ADMA Biologics Inc (NASDAQ:ADMA) Sees Large Decline in Short Interest

ADMA Biologics Inc (NASDAQ:ADMA) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totaling 22,175,506 shares, a decline of 14.1% from the March 15th total of 25,826,838 shares. Based on an average daily volume of 13,551,247 shares, the days-to-cover ratio is currently 1.6 days. Approximately 9.6% of the company’s shares are short sold.

ADMA Biologics Stock Performance

Shares of ADMA Biologics stock opened at $11.01 on Friday. The company has a current ratio of 6.71, a quick ratio of 3.74 and a debt-to-equity ratio of 0.16. The business has a 50-day moving average price of $13.45 and a two-hundred day moving average price of $15.80. ADMA Biologics has a 1-year low of $7.21 and a 1-year high of $25.67. The company has a market cap of $2.62 billion, a P/E ratio of 18.35 and a beta of 0.82.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The firm had revenue of $139.16 million during the quarter, compared to the consensus estimate of $139.80 million. During the same period last year, the business posted $0.46 EPS. The business’s revenue was up 18.4% compared to the same quarter last year. As a group, analysts anticipate that ADMA Biologics will post 0.51 EPS for the current year.

Key ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Analysts’ consensus target moved higher — a recent note reports a $28.00 average price target for ADMA, which supports upside versus current levels and may be driving some buying interest. ADMA Biologics Inc (NASDAQ:ADMA) Receives $28.00 Average Target Price from Analysts
• Positive Sentiment: Stock appears on bullish screens — ADMA was named among “most undervalued” biotech picks and also listed as a top low‑priced biotech stock, which can attract retail and value‑oriented buyers. 5 Most Undervalued Biotech Stocks to Buy Right Now
• Positive Sentiment: Additional retail/coverage mentions — ADMA also appears on a “best low priced biotech” list, reinforcing visibility among bargain‑hunting investors. 5 Best Low Priced Biotech Stocks to Invest In
• Neutral Sentiment: Market commentary urges reassessment after recent volatility — a finance piece suggests investors should re‑evaluate ADMA given recent price swings, highlighting that both upside and downside catalysts are in play. Is It Time To Reassess ADMA Biologics (ADMA) After Recent Share Price Volatility
• Negative Sentiment: Multiple securities‑fraud investigations are pending — Lowey Dannenberg is investigating potential federal securities‑law violations linked to a short‑seller report alleging channel‑stuffing and other issues; this raises the risk of litigation, regulatory scrutiny and increased volatility. ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
• Negative Sentiment: Additional law firms have opened investigations — Rosen Law Firm and Bleichmar Fonti & Auld LLP have announced probes into potential misleading disclosures and channel‑stuffing claims, compounding legal exposure and headline risk. ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights Stock-Notification: ADMA Biologics (NASDAQ:ADMA) Securities Fraud Investigation Over Channel Stuffing Claims is Ongoing – Contact BFA Law if You Lost Money

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the transaction, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at approximately $7,292,958. The trade was a 2.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steve Elms purchased 7,000 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was bought at an average cost of $15.67 per share, with a total value of $109,690.00. Following the purchase, the director owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. This trade represents a 0.34% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 3.50% of the company’s stock.

Institutional Trading of ADMA Biologics

A number of large investors have recently bought and sold shares of the business. State Street Corp grew its holdings in ADMA Biologics by 0.3% during the 4th quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock worth $248,014,000 after acquiring an additional 35,614 shares during the period. Sachem Head Capital Management LP grew its stake in shares of ADMA Biologics by 27.0% in the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock valued at $207,480,000 after buying an additional 2,415,000 shares during the period. Westfield Capital Management Co. LP grew its stake in shares of ADMA Biologics by 36.9% in the 4th quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock valued at $127,551,000 after buying an additional 1,886,105 shares during the period. Capital Research Global Investors grew its stake in shares of ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after buying an additional 3,383,559 shares during the period. Finally, Nuveen LLC grew its stake in shares of ADMA Biologics by 3.5% in the 4th quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock valued at $108,097,000 after buying an additional 202,245 shares during the period. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Mizuho decreased their price target on ADMA Biologics from $30.00 to $24.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. Wall Street Zen cut ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Zacks Research raised ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $28.00.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.